Effect of eplerenone in systolic dysfunction complicating acute myocardial infarction heart failure patients

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 21 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eplerenone (Primary)
Indications Cardiovascular disorders; Heart failure; Left ventricular dysfunction; Myocardial infarction
Focus Therapeutic Use
Acronyms EPHESUS
Sponsors Pfizer

01 Apr 2022 Results assessing Serum sodium and eplerenone use in patients with a myocardial infarction and left ventricular dysfunction or heart failure published in the Clinical Research in Cardiology
02 Mar 2020 Results of myocardial reperfusion reverses the J-curve association of cardiovascular risk and diastolic blood pressure in patients with left ventricular dysfunction and heart failure after myocardial infarction has been published in the European Heart Journal
05 Nov 2010 New trial record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com